Silence Therapeutics PLC ADR SLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Silence Therapeutics to Participate in Three September Investor Conferences
-
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
-
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
-
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
-
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
-
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
-
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Trading Information
- Previous Close Price
- $9.35
- Day Range
- $8.66–9.22
- 52-Week Range
- $4.19–17.58
- Bid/Ask
- $8.66 / $8.68
- Shares Outstanding
- 62.15M
- Market Cap
- $539.50M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 681.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 88
Valuation
|
Metric
|
SLN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.89 |
Price/Sales | 681.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLN
|
|---|---|
Quick Ratio | 6.40 |
Current Ratio | 7.42 |
Interest Coverage | — |
Quick Ratio
SLN
Profitability
|
Metric
|
SLN
|
|---|---|
Return on Assets (Normalized) | −41.88% |
Return on Equity (Normalized) | −87.47% |
Return on Invested Capital (Normalized) | −87.31% |
Return on Assets
SLN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@!HwN^ | LOCK|vln# | $127B | |||
| Moderna Inc
MRNA
| LOCK|@hmr$xF | LOCK|#f< | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?^MT$M | LOCK|<qQh | $81B | |||
| argenx SE ADR
ARGX
| LOCK|J$G?sG | LOCK|pGN | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>Lr?@vK | LOCK|#% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&Rrmwf | LOCK|^?#$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x><<^?c | LOCK|lJHZ | $27B | |||
| Incyte Corp
INCY
| LOCK|^%^@v& | LOCK|%% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!%<&f!% | LOCK|Dv | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|M>>Q#% | LOCK|?T< | $14B |
United States